Glenmark Pharmaceuticals Limited gained attention after its subsidiary received US Food and Drug Administration approval for fluticasone propionate inhalation aerosol. The drug targets a $520 million respiratory market and qualifies for 180-day competitive generic therapy exclusivity. The product will launch in March 2026 in the US.